PEPperPRINT

PEPperPRINT

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6M

Overview

PEPperPRINT is a privately held, revenue-generating platform and services company specializing in high-density peptide microarray technology. Its proprietary laser-printing technology enables the combinatorial synthesis of highly overlapping peptide libraries on microarrays, allowing for high-resolution, high-throughput analysis of linear and conformational epitopes. The company serves research and diagnostic needs in immunology, infectious disease, and antibody development, providing critical tools for characterizing immune responses. PEPperPRINT operates from its headquarters in Heidelberg, Germany, leveraging its strong IP position and scientific expertise.

Infectious DiseaseImmunologyOncology

Technology Platform

Proprietary combinatorial synthesis of high-density peptide microarrays using amino acid toner particles and a custom 24-color laser printer. Enables production of highly overlapping peptide libraries for high-resolution, high-throughput epitope mapping and antibody profiling.

Funding History

2
Total raised:$6M
Series A$4.5M
Seed$1.5M

Opportunities

Growing demand for high-resolution immune profiling in vaccine development, therapeutic antibody characterization, and personalized medicine presents a significant expansion opportunity.
The platform is also well-suited for rapid response to emerging pathogens, as demonstrated with its SARS-CoV-2 microarray, positioning it for future pandemic preparedness contracts.

Risk Factors

Competition from alternative epitope mapping technologies (e.g., phage display, NGS-based assays) and potential technological obsolescence are key risks.
The company's reliance on research budgets from academia and biotech makes it vulnerable to funding cycles and economic downturns.

Competitive Landscape

PEPperPRINT competes with providers of traditional epitope mapping services (e.g., ELISA-based, SPOT synthesis) and other peptide array technologies. Its key differentiators are the ability to map conformational epitopes, single-amino-acid resolution, high throughput, and lower sample requirements. It faces competition from larger proteomics and life science tools companies that may offer broader but less specialized platforms.